Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
      • Partners
  • Technology
      • Advantages of Emergex’s Vaccines
  • Pipeline
  • Media Centre
    • In the News
    • Press Releases
  • Careers
  • Contact Us
  • Menu Menu
You are here: Home1 / Pipeline

Pipeline

Emergex has a growing pipeline of CD8+ T cell Adaptive Vaccine candidates. We have initiated first-in-human Phase I clinical trials conducted in Switzerland for Dengue Fever and COVID-19 vaccine candidates. We are also actively developing our programmes for seasonal Influenza and Chikungunya through active preclinical work supported by partner organisations.

Our Technology Vaccine Advantages
Pipeline 1507

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top